^
Association details:
| Biomarker: | MET expression + HER-2 expression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Orpathys (savolitinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer
Published date:
09/07/2021
Excerpt:
...the activity of volitinib combined with trastuzumab was explored in three gastric cancer PDX models with HER2 and MET positive expressions...the combination therapy of volitinib and trastuzumab played a synergistic antitumor activity with TGIs 85.6% in PDX 2, 62.8% in PDX 8, and 68.2% in PDX9.
DOI:
10.3389/fonc.2021.719217
